ReviewBrain & spine2025
Review of treatment modalities and clinical outcome of giant saccular posterior cerebral artery aneurysms.
Review in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Giant saccular posterior cerebral artery (PCA) aneurysms are rare lesions carrying significant morbidity due to mass effect and present therapeutic challenges, mainly due to the challenging approach required for aneurysm obliteration. Research question: To review treatment modalities and outcomes of patients harboring giant (>2.5 cm) PCA saccular aneurysms distal to the basilar bifurcation. Materials and methods: A systematic literature review through PubMed and Scopus to identify cases of giant saccular PCA aneurysms treated either microsurgically or endovascularly. Patients' demographics, aneurysm size, preoperative and postoperative neurologic status, clinical outcomes and follow-up information were retrieved. Results: Data from 33 studies including 55 patients were obtained. Mean patient age was 34.35 years. Mean maximum aneurysm diameter was 38.48 mm. Presentation was aneurysm rupture in 30.9 %, headache in 23.6 %, hemiparesis or tetraparesis in 12.7 %, hemianopsia in 10.9 % and hydrocephalus in 5.5 %. At least 30.9 % had significant brainstem compression. Treatment was endovascular in 23.6 %, microsurgical in 67.3 % and combined in 9.1 %. Debulking to reduce mass effect was required in 32.4 %. Preoperative mRS ranged from 1 to 5. A favorable outcome (mRS 0-2) was reported on 92.7 % of cases. Death rate was 3.6 %. The PCA was sacrificed in 40 % of the patients without severe neurologic morbidity. Follow-up ranged from 1 week to 11 years. Discussion and conclusion: Giant PCA aneurysms are amenable to both treatment modalities. PCA sacrifice may be required and is often well tolerated, presumably due to the rich collateral supply. Mass effect may necessitate debulking. PCA bypass may be required, but carries significant morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.